First report of anti-TIF1γ dermatomyositis in a patient with myelodysplastic syndrome
- B. Palterer Experimental and Clinical Medicine Dept., University of Florence, Florence, Italy.
-
G. Vitiello
|
gianfranco.vitiello@unifi.it
Experimental and Clinical Medicine Dept., University of Florence, Florence, Italy.
- D. Cammelli Rheumatology Section/Immunoallergology Unit, AOU-Careggi, Florence, Italy.
Abstract
Inflammatory myopathies as para-neoplastic phenomena were first described by Sterz in 1916. Recently, myositis specific autoantibodies were described in cancer-associated myositis. Anti-transcription intermediary factor 1 gamma (anti-TIF1γ) antibodies have been found in both young adults affected by juvenile dermatomyositis and in elderly patients with cancer-associated myositis. In this regard, we report herein the first case of anti-TIF1γ dermatomyositis secondary to a myelodysplastic syndrome.
Downloads
Download data is not yet available.
Published
2017-08-03
Keywords:
Myelodisplastic syndrome, Myositis specific autoantibodies, Anti-TIF1γ, Dermatomyositis.
Statistics
- Abstract views: 922
- PDF: 524
How to Cite
Palterer, B., Vitiello, G., & Cammelli, D. (2017). First report of anti-TIF1γ dermatomyositis in a patient with myelodysplastic syndrome. Reumatismo, 69(2), 75-77. https://doi.org/10.4081/reumatismo.2017.923
Copyright (c) 2017 B. Palterer, G. Vitiello, D. Cammelli
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
